论文部分内容阅读
为了探讨左旋门冬酰胺酶为主的改良VDLP方案治疗NK/T细胞淋巴瘤的疗效及毒副反应,分析2006-03-1-2009-10-1我院收治的24例初治NK/T细胞淋巴瘤患者,治疗方案均选用改良VDLP方案,所有患者均接受2～6个周期,中位3.5个周期,病灶局限的患者,化疗后加用侵犯野放疗。24例患者中,总有效率70.8%(17/24),完全缓解率(CR)62.5%(15/24),部分缓解率(PR)8.3%(2/24),病情稳定(SD)12.5%(3/24),4例恶化(PD)16.6%(4/24)。中位随访26(12～49)个月,全组预期3年生存率为66.7%;主要不良反应为骨髓抑制,Ⅲ～Ⅳ度粒细胞减少占25%,无治疗相关死亡。初步研究提示,左旋门冬酰胺酶为主的VDLP方案治疗NK/T细胞淋巴瘤疗效好,毒副反应小且耐受性好,值得临床推荐使用。
In order to investigate the efficacy of L-asparaginase-based modified VDLP regimen in the treatment of NK / T-cell lymphoma and its toxicities and side effects, 24 patients with untreated NK / T Patients with cell lymphoma, treatment options were selected modified VDLP program, all patients received 2 to 6 cycles, the median 3.5 cycles, the lesions in patients with localized chemotherapy after chemotherapy plus invasion. Among the 24 patients, the total effective rate was 70.8% (17/24), the complete response rate (CR) 62.5% (15/24), the partial response rate 8.3% (2/24) and the stable condition (SD) 12.5 % (3/24), 4 cases of deterioration (PD) 16.6% (4/24). The median follow-up was 26 (12-49) months. The expected 3-year overall survival rate was 66.7%. The major adverse reactions were myelosuppression, and the third to fourth degree neutropenia accounted for 25%. No treatment-related deaths occurred. Preliminary studies suggest that L-asparaginase-based VDLP regimen for the treatment of NK / T-cell lymphoma with good efficacy, small side effects and good tolerability, it is recommended for clinical use.